These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of diffuse hepatic uptake following I-131 therapy for differentiated thyroid cancer. Ferris HA; Williams G; Parker JA; Garber JR Endocr Pract; 2013; 19(2):263-7. PubMed ID: 23529347 [TBL] [Abstract][Full Text] [Related]
4. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma. Scheffel RS; Zanella AB; Dora JM; Maia AL Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175 [TBL] [Abstract][Full Text] [Related]
5. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma. Long B; Li L; Yao L; Chen S; Yi H; Ye X; Xu D; Wu P J Cancer Res Ther; 2015 Nov; 11 Suppl():C244-7. PubMed ID: 26612446 [TBL] [Abstract][Full Text] [Related]
6. [Size of postoperative thyroid remnant as oncological quality parameter]. Dralle H Chirurg; 2014 Mar; 85(3):256. PubMed ID: 24496752 [No Abstract] [Full Text] [Related]
7. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients. Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569 [TBL] [Abstract][Full Text] [Related]
8. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005 [TBL] [Abstract][Full Text] [Related]
9. Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation. Oltmann SC; Schneider DF; Leverson G; Sivashanmugam T; Chen H; Sippel RS Ann Surg Oncol; 2014 Apr; 21(4):1379-83. PubMed ID: 24378987 [TBL] [Abstract][Full Text] [Related]
10. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence. Rosário PW; Calsolari MR Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207 [TBL] [Abstract][Full Text] [Related]
11. Correlation between cervical uptake and results of postsurgical radioiodine ablation in patients with thyroid carcinoma. Rosário PW; Maia FF; Cardoso LD; Barroso A; Rezende L; Padrão EL; Purisch S Clin Nucl Med; 2004 Jun; 29(6):358-61. PubMed ID: 15166882 [TBL] [Abstract][Full Text] [Related]
12. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect. Yap BK; Murby B J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114 [TBL] [Abstract][Full Text] [Related]
13. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Kuo EJ; Goffredo P; Sosa JA; Roman SA Thyroid; 2013 Oct; 23(10):1305-11. PubMed ID: 23600998 [TBL] [Abstract][Full Text] [Related]
15. Thyroid remnant ablation following administration of a diagnostic dose of iodine-131 under thyrogen stimulation. Wu D; Fink-Bennett D; Campbell J Thyroid; 2014 May; 24(5):924-5. PubMed ID: 24483713 [No Abstract] [Full Text] [Related]
16. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake. Rosário PW; Reis JS; Barroso AL; Rezende LL; Padrão EL; Fagundes TA Nucl Med Commun; 2004 Nov; 25(11):1077-81. PubMed ID: 15577584 [TBL] [Abstract][Full Text] [Related]
17. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064 [TBL] [Abstract][Full Text] [Related]
18. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients. Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109 [TBL] [Abstract][Full Text] [Related]
19. Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features. Messuti I; Corvisieri S; Bardesono F; Rapa I; Giorcelli J; Pellerito R; Volante M; Orlandi F Eur J Endocrinol; 2014 May; 170(5):659-66. PubMed ID: 24510913 [TBL] [Abstract][Full Text] [Related]
20. Thyroid Remnant Estimation by Diagnostic Dose (131)I Scintigraphy or (99m)TcO4(-) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131)I Imaging. Liu G; Li N; Li X; Chen S; Du B; Li Y Biomed Res Int; 2016; 2016():4763824. PubMed ID: 27034938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]